Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-022 in R/R CLL/SLL
NCT03493217Phase 2Unknown
- Sponsor
- InnoCare Pharma
- Start
- Apr 2018
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of orelabrutinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by InnoCare Pharma. Primary endpoint: Objective Response Rate up to 3 years. Status: unknown.
02
Drugs
orelabrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT03493217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03493217.